Answers are grounded in this paper and cite their sources.
A decade ago, it seemed clear that our burgeoning knowledge of the molecular identities of tumor-associated antigens and a deeper understanding of basic immunology would point the way to an effective therapeutic cancer vaccine. Significant progress has been made and objective regressions after immune-based treatments are observed in some patients -even in those with bulky, metastatic disease. Notwithstanding this progress, we do not yet have a cancer vaccine in hand that can reliably increase patient survival or induce tumor destruction.
No takes yet. Share an insight, caveat, or question.
Yu et al. (2002) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: